President Donald J. Trump signed an executive order on Saturday aimed at speeding up the development and approval of psychedelic-based treatments for serious mental illness in the United States.

The directive targets a range of conditions, including major depressive disorder and substance use disorders, specifically for patients who have not responded to traditional therapies.

The order signals a significant shift in federal drug policy by prioritizing the evaluation of substances like psilocybin and ibogaine, which are currently classified as Schedule I controlled substances. While advocates have hailed the move as a breakthrough for mental health innovation, medical experts have raised questions regarding the safety profile of some compounds and the practicalities of their implementation.

“Today’s Executive Order reflects growing recognition that modern mental health challenges demand new approaches,” said Betty Aldworth, Co-Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Key Provisions

The primary objective of the order is to streamline the regulatory pathway for “Breakthrough Therapy” drugs. Specifically, the directive instructs the Food and Drug Administration (FDA) to issue Commissioner’s National Priority Vouchers for psychedelic drugs that have already received breakthrough designations. These vouchers are designed to accelerate the review process, potentially reducing wait times for federal approval from months to weeks.

Furthermore, the order expands the “Right to Try” framework to include investigational psychedelic compounds. This provision is intended to allow patients with life-threatening or severely debilitating conditions to access experimental treatments—including ibogaine—provided they have met basic safety requirements and are currently under FDA review.

To bolster research at the local level, the Secretary of Health and Human Services (HHS) has been directed to allocate $50 million through the Advanced Research Projects Agency for Health (ARPA-H). This funding is earmarked to match state-level investments in psychedelic research programs. The move appears to follow the lead of states like Texas, which recently authorized state-funded research into ibogaine for veterans.

Federal Coordination and Scheduling

The executive order also mandates increased inter-agency cooperation. The HHS, FDA, and Department of Veterans Affairs (VA) are required to sign data-sharing agreements to pool clinical trial results. The goal is to provide the FDA with a more robust evidence base to facilitate timely evaluations.

Addressing the legal status of these substances, the order directs the Attorney General to initiate a review of relevant products immediately following the successful completion of Phase 3 clinical trials. This is intended to ensure that if a drug is approved by the FDA, the process of rescheduling it under the Controlled Substances Act can occur as quickly as possible.

What the Order Doesn’t Do

Despite the sweeping language of the directive, several legal and medical hurdles remain. The order does not immediately legalize or “deschedule” psychedelics. Substances such as MDMA, LSD, and psilocybin remain in the most restrictive federal category for illegal drugs. Any rescheduling remains contingent on the completion of rigorous Phase 3 clinical trials and subsequent FDA approval.

Importantly, the order does not mandate insurance coverage for these experimental therapies. Industry analysts noted that because these treatments remain largely unapproved, they are unlikely to be covered by private or public insurance in the near term, potentially limiting access to those who can afford out-of-pocket costs at private clinics.

“Today, people desperate for healing are traveling abroad or self-medicating with impure substances and little support. Efforts like today’s Executive Order must be paired with regulated psychedelics, provider training, and robust insurance coverage,” said Aldworth.

Finally, the order does not bypass existing safety protocols. While it seeks to “accelerate” the process, drugs must still demonstrate safety and efficacy through the standard clinical trial pipeline.

Medical and Scientific Context

The administration’s focus on ibogaine has drawn particular attention. Derived from a West African shrub, ibogaine has been studied for its potential to interrupt opioid addiction and treat post-traumatic stress disorder (PTSD). However, it is also known for potential cardiac toxicity. Some researchers expressed concern that emphasizing ibogaine over other psychedelics with more established safety profiles could be premature.

“As federal agencies move to reduce longstanding barriers to research, it is essential that progress across this broader class of compounds remains grounded in rigorous science, careful evaluation, and a commitment to patient safety,” said Ismail L. Ali, J.D., Co-Executive Director of MAPS. 

The advocate has called for “alignment with global public health principles” when working with ibogaine and the Iboga plant from which it’s extracted.

“Ibogaine has the potential to address the devastating crisis of opioid use disorder. However, because iboga is a limited resource, mass production of ibogaine can harm the people, traditions, and land where iboga is grow,” he said.

The order represents a rare area of emerging bipartisan interest, as lawmakers from both parties have expressed support for expanding research into how psychedelics might assist veterans and those struggling with treatment-resistant depression. However, the success of the initiative will ultimately depend on the results of ongoing clinical trials and the ability of federal agencies to navigate the complex safety and regulatory requirements involved in bringing Schedule I substances to the medical market.

Market Impact

The news provided a boost for companies in the psychedelics sector that are publicly traded, reflecting growing investor confidence in the field. Shares from Compass Pathways, a company with a Phase 3 program in psilocybin, were up 43% on Monday. AtaiBeckley was up 24% and GH Research 16%.

Picture: courtesy of the White House.

The European Medicines Agency is taking steps to rethink how certain high-need medicines reach patients, with a new concept paper proposing a more flexible, evidence-based pathway for cancer therapies. While the focus is paediatric oncology, the implications may extend far beyond cancer, raising questions about whether similar approaches could eventually support the development of psychedelic treatments.

The “Weight of Evidence” Model

Published last month, the EMA’s concept paper outlines plans for a reflection paper on how “proof-of-concept” data should be used to guide early-stage drug development. At its core is a shift away from rigid data requirements toward a “weight of evidence” model, where regulators assess the totality of available data, including non-clinical studies, early clinical signals, and biological rationale.

This approach is already gaining traction in oncology, particularly in paediatric settings where patient populations are small and traditional large-scale trials are often unfeasible. In such cases, regulators are increasingly willing to rely on mechanistic understanding and preclinical evidence to justify moving into clinical trials earlier, provided there is a strong scientific rationale and unmet medical need.

The EMA’s concept paper emphasises that development decisions should be grounded in several key domains, including mechanism of action, disease biology, pharmacology, and safety, as well as the broader clinical context. Rather than requiring exhaustive datasets upfront, the agency is signalling openness to iterative development, where evidence is built progressively and regulatory decisions evolve alongside the data.

For the psychedelics field, this raises a clear question: could a similar framework accelerate the path to approval?

A shift toward mechanism-of-action–based regulation in psychedelics could, in theory, reduce the need to pursue separate approvals for each diagnostic category, such as depression or PTSD, by anchoring use to a shared underlying biology.

If regulators accept that psychedelic therapies exert their primary effect through defined pathways, for example 5-HT2A receptor activation leading to increased neuroplasticity and network-level brain changes, then the relevant treatment population could be framed around patients exhibiting that dysfunction rather than a specific DSM label. In this model, a single approval could cover multiple conditions where the same mechanism is implicated, provided there is sufficient evidence linking that pathway to clinical benefit across those populations.

This would shift development away from duplicative, indication-by-indication trials toward demonstrating consistent mechanistic effects and reproducible outcomes in biologically defined subgroups.

There are other parallels between the regulatory paths described in the paper and psychedelics. Psychedelic therapies are often being developed for conditions where unmet need remains high and patient populations can be difficult to study using conventional trial designs. Like paediatric oncology, these indications may benefit from more flexible approaches that incorporate multiple forms of evidence.

However, important differences remain.

Oncology drug development is underpinned by well-established biological models and biomarkers, allowing regulators to link mechanism of action to clinical outcomes with a relatively high degree of confidence. In contrast, the mechanisms underlying psychedelic therapies are still being defined, spanning pharmacological effects, neural network changes, and the subjective therapeutic experience itself.

The EMA’s framework places significant weight on the relevance and reliability of non-clinical models, an area where psychedelics currently face limitations. Translating findings from animal studies to complex psychiatric outcomes in humans remains a challenge, and there is no widely accepted biomarker that can serve as a proxy for therapeutic response.

Endpoints also differ. Cancer trials can rely on objective measures such as tumour progression or survival, whereas psychedelic studies typically depend on subjective scales and patient-reported outcomes. This makes it more difficult to integrate different sources of evidence into a unified regulatory decision.

Even so, the direction of travel is notable. By formalising a weight-of-evidence approach and emphasising mechanism-driven development, the EMA is signalling greater flexibility in how innovative therapies are assessed. If these principles are applied more broadly across therapeutic areas, they could eventually lower some of the structural barriers facing psychedelic drug development.

For now, the concept paper remains focused on oncology, and significant scientific and regulatory hurdles would need to be addressed before such a model could be extended to psychedelics. But as regulators continue to adapt to emerging forms of medicine, the boundaries between therapeutic areas may become less rigid.

In that context, the EMA’s latest move may not just reshape cancer drug development, but also offer an early glimpse of how the next generation of psychiatric treatments could be evaluated.

Picture: EMA headquarters in Amsterdam. Courtesy of EMA.

In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental regulatory shifts began to reshape investor expectations, policy debates, and the direction of research across business, government, and academia.

Business and Investment

Big Pharma joins the sector as key companies push research goals forward 

2025 saw pivotal corporate developments across the major psychedelic medicine companies, uplifting investor expectations and clarifying some regulatory pathways. A slow but steady loosening of regulatory hurdles and positive clinical results have breathed new life into the sector, with some analysts reporting refreshed investor interest and a possible end to the capital drought that has slashed the space in recent years.

Big Pharma giant AbbVie, known for blockbuster drugs in immunology and oncology, agreed to acquire Gilgamesh Pharmaceuticals’ lead experimental therapy, bretisilocin, in a deal reportedly worth $1.2 billion. Bretisilocin is a novel psychedelic targeting major depressive disorder. The event is a signal of Big Pharma entering the space and prioritising shorter-acting serotonin-2A modulators for depression.

Compass Pathways reached a major clinical inflection point, reporting positive results in its first Phase 3 COMP360 trial and accelerating commercial launch planning. CEO Kabir Nath recently told Psychedelic Health that positive talks with the FDA indicate that the company “could potentially be looking at a launch in early 2027” for its flagship program with synthetic psilocybin.

Beckley Psytech, which is supported by Atai Life Sciences secured a Breakthrough Therapy designation by the FDA for BPL-003, a novel intranasal formulation of 5-MeO-DMT, reinforcing regulatory momentum the compound known as “toad venom.” The FDA’s decision follows promising results from a Phase 2b clinical trial, which demonstrated that a single dose of the compound led to rapid and sustained reductions in depressive symptoms within 24 hours, with effects lasting up to eight weeks.

Cybin advanced multiple clinical programs, completing enrollment milestones for CYB004, a version of DMT targeting generalised anxiety disorder and maintaining progress on CYB003, a 5-HT2A receptor agonist similar to psilocybin for major depressive disorder. The company secured financing to extend runway and protect intellectual property across its portfolio.

MindMed reported faster than expected enrollment in its Phase 3 MM120 program, an analog of LSD targeting generalised anxiety disorder, updating timelines for topline readouts and emphasising oral LSD analogs as a differentiated regulatory route. 

Policy and Regulation

Major global players reschedule psychedelics for medical use

2025 marked a year of uneven but consequential movement in psychedelic policy and regulation, with a small number of jurisdictions taking concrete steps toward medical access while others remained in exploratory or preparatory phases.

The UK’s regulatory landscape for psychedelic medicine continued to evolve through policy dialogue and research initiatives, although no formal legalisation or medical scheduling changes occurred. The Royal College of Psychiatrists published a position statement reviewing evidence on psilocybin, MDMA, LSD, and ketamine, concluding that current data are promising but insufficient to recommend routine clinical use outside licensed settings, emphasising the need for more robust trials and caution against premature adoption.

This year, the UK government agreed in principle with key Advisory Council on the Misuse of Drugs (ACMD) recommendations to ease barriers to Schedule 1 psychedelic research. Part of the recommendations included allowing universities and hospitals to conduct research without a Home Office domestic licence, and ethically approved clinical trials to be exempt from additional licensing. Though these changes are not in effect yet, they could be enacted after a pilot program takes place.

Australia continued to stand out as a global pioneer in medical access. Since 1 July 2023, MDMA and psilocybin have been rescheduled from strictly prohibited status to controlled medicines, meaning authorised psychiatrists can legally prescribe them for treatment-resistant depression and post-traumatic stress disorder. From 6 January 2025, new quality standards for MDMA and psilocybin products came into force, requiring compliance for all supplied APIs and finished products. The Department of Veterans’ Affairs approved funding for psychedelic-assisted psychotherapy for eligible veterans, marking a first step toward public payer support.

In Europe, Germany became the first EU country to establish a formal compassionate use access programme for psilocybin, enabling adults with treatment-resistant depression to receive psilocybin therapy at specialised centres under a regulated framework prior to full regulatory approval. This initiative, supported by the German Federal Institute for Drugs and Medical Devices and implemented at facilities in Mannheim and Berlin, marks a landmark step in European psychedelic policy.

The Czech Republic is set to become one of the first European countries to legalise medical use of psilocybin from January 1, 2026. The outgoing government approved legislation late in 2025 allowing psychiatrists and psychotherapists to administer psilocybin for conditions such as cancer-related depression and serious clinical depression when other registered treatments have failed or are not tolerated. Psilocybin therapy will be introduced under controlled clinical conditions at qualified facilities.

In the United States, action remained at the state-level. Oregon and Colorado, having already legalised regulated access to natural psychedelics including psilocybin and launched supervised service programs, continued to refine implementation and data collection frameworks in 2025. Meanwhile, numerous state legislatures introduced bills to advance psychedelic therapy access, and Massachusetts held legislative hearings on psychedelic therapy programmes, reflecting growing political engagement despite the absence of federal reclassification.

Science and Research

New data from real-world applications and feedback from regulatory agencies inform research 

In the academic side of the equation, 2025 consolidated a transition from exploratory efficacy signals to confirmatory, regulation-relevant evidence, while underscoring persistent limitations: small sample biases, variable control conditions, and unresolved questions about long-term safety and scalability.

One of the most significant published findings came from a phase 2 trial in cancer patients, where a single dose of psilocybin combined with therapy produced sustained reductions in depression and anxiety, with many participants maintaining benefits up to two years later. 

Alongside observational outcomes, mid-stage clinical studies have found LSD may ease anxiety symptoms for up to three months in people with moderate-to-severe generalised anxiety disorder, with a significant proportion of participants still in remission at 12 weeks.

For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment, sharing insights into how the legal, real-world version of the treatment works, who can access it, and whether the benefits observed in trials translate to broader populations.

Longitudinal data strengthened claims of sustained benefit in selected cohorts. Multiple follow-up reports published in 2025 described durable antidepressant effects at extended intervals after single or limited psilocybin administrations, although most samples remained small and non-randomised. These findings have prompted calls for larger, controlled long-term studies. 

The FDA’s public release of the complete response letter on Lykos Therapeutics’ trials on MDMA therapy highlighted durability and safety questions, prompting re-examination of trial design and participant selection in MDMA and related programmes.

Cambridge Psychedelic Research Group formally launched in 2025, creating a new hub for clinical trials and interdisciplinary research in the UK, including pathways for patient recruitment and academic-industry collaboration.

Illustrated image made using AI tools.